The aim of this study was to review the global burden of RSV disease in children and update current published data. 3 estimated that there were 33.8 million new episodes of RSV-associated acute lower respiratory infections (ALRIs) worldwide in children <5 years of age, including 3.4 million episodes of severe RSV-ALRI requiring hospitalization with 66,000–190,000 deaths from RSV-associated ALRI in 2005. The reported incidence and mortality of RSV acute respiratory infection (ARI) is highly variable by geographic location, case ascertainment, populations under surveillance, and the diagnostic method used to identify RSV. In addition to severe acute disease, evidence also suggests that children who had severe RSV infection early in life are more likely to develop subsequent wheezing during early childhood 6 and hyperreactive airways and asthma later in life. 1- 3 Certain high-risk groups, including premature infants infants with underlying medical conditions such as chronic lung disease of prematurity (CLDP) or bronchopulmonary dysplasia (BPD) hemodynamically significant congenital heart disease (hsCHD) immunocompromised conditions or severe neuromuscular disease, are prone to serious disease due to RSV with higher morbidity and mortality rates than those without these conditions. RSV disease manifestations in children range from mild upper respiratory tract infection to severe respiratory infection including pneumonia or bronchiolitis which can lead to hospitalization and serious complications such as respiratory failure.
Respiratory syncytial virus (RSV) is a seasonal disease and causes an enormous burden on health systems across the world. Moreover, case-fatality ratios cannot be translated to population-based mortality. An important limitation of case-fatality ratios is the absence of individual patient characteristics of non-surviving patients. These data affirm the importance of RSV disease in the causation of hospitalization and as a significant contributor to pediatric mortality and further demonstrate gestational age as a critical determinant of disease severity. Conclusions: A substantial proportion of RSV-associated morbidity occurs in the first year of life, especially in children born prematurely.
The global RSV-ARI hospitalization estimates, reported per 1,000 children per year (95% Credible Interval (CrI), were 4.37 (2.98, 6.42) among children <5 years, 19.19 (15.04, 24.48) among children <1 year, 20.01 (9.65, 41.31) among children <6 months and 63.85 (37.52, 109.70) among premature children <1 year. Fifty-five studies were included from 32 countries. Results: Five thousand two hundred and seventy-four references were identified. Main outcomes were hospitalization for severe RSV-ARI and death. Methods: Systematic literature review and meta-analysis of published data from 2000 onwards, reporting on burden of acute respiratory infection (ARI) due to RSV in children. We aimed to review the current literature on the incidence and mortality of severe RSV in children globally.
Background: Respiratory syncytial virus (RSV) is a major public health burden worldwide.
0 kommentar(er)
